ロード中...

Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition

BACKGROUND: Patients with pulmonary arterial hypertension (PAH) are treated with vasodilators, including endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, soluble guanylyl cyclase activators, and prostacyclin. Despite recent advances in pharmacotherapy for individuals w...

詳細記述

保存先:
書誌詳細
出版年:J Transl Med
主要な著者: Cavasin, Maria A, Demos-Davies, Kimberly M, Schuetze, Katherine B, Blakeslee, Weston W, Stratton, Matthew S, Tuder, Rubin M, McKinsey, Timothy A
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2014
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4255666/
https://ncbi.nlm.nih.gov/pubmed/25425003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-014-0314-y
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!